2.26
Proqr Therapeutics N V stock is traded at $2.26, with a volume of 446.75K.
It is up +4.15% in the last 24 hours and up +11.33% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.17
Open:
$2.18
24h Volume:
446.75K
Relative Volume:
1.11
Market Cap:
$237.78M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.9662
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-5.83%
1M Performance:
+11.33%
6M Performance:
+4.63%
1Y Performance:
+20.21%
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PRQR
Proqr Therapeutics N V
|
2.26 | 228.59M | 7.05M | -30.43M | 21.84M | -0.3788 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
Apr-29-25 | Initiated | Evercore ISI | Outperform |
Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
Jan-10-25 | Initiated | Oppenheimer | Outperform |
Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
Feb-11-22 | Downgrade | Stifel | Buy → Hold |
Feb-01-22 | Initiated | Raymond James | Strong Buy |
May-03-21 | Initiated | Stifel | Buy |
Mar-25-21 | Reiterated | Citigroup | Buy |
Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
Nov-15-18 | Initiated | Citigroup | Buy |
Sep-19-18 | Initiated | Evercore ISI | Outperform |
Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
Oct-15-14 | Initiated | Deutsche Bank | Buy |
Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia
Is ProQR Therapeutics N.V. stock a growth or value playVerified Return Tips - Newser
Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com
What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional
What analysts say about ProQR Therapeutics N.V. stockUnprecedented profit potential - Autocar Professional
Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance
ProQR Therapeutics N.V. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
How ProQR Therapeutics N.V. stock performs during market volatilityProven Win Setups - Newser
What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com
ProQR submits clinical trial application for RNA editing therapy By Investing.com - Investing.com India
ProQR Seeks EU Approval for Liver Cell Protein Trial - MarketScreener
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire
ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):